<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-ONN-17012370</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2017-08-15</date_registration>
      <primary_sponsor>The First Affiliated Hospital of Sun Yat-sen University</primary_sponsor>
      <public_title>The prospective, controlled, multi-center phase III clinical trial of Allo-HSCT and double ASCT in patients with high-risk multiple myeloma</public_title>
      <acronym />
      <scientific_title>The prospective, controlled, multi-center phase III clinical trial of Allo-HSCT and double ASCT in patients with high-risk multiple myeloma</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2018-01-01</date_enrolment>
      <type_enrolment />
      <target_size>Group of tandem autologous stem-cell transplantation:208;Group of allogeneic stem-cell transplantation:103;</target_size>
      <recruitment_status>Pending</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=21073</url>
      <study_type>Observational study</study_type>
      <study_design>Non randomized control</study_design>
      <phase>New Treatment Measure Clinical Study</phase>
      <hc_freetext>Multiple myeloma</hc_freetext>
      <i_freetext>Group of tandem autologous stem-cell transplantation:Double ASCT;Group of allogeneic stem-cell transplantation:Allo-SCT;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Beihui Huang</firstname>
        <middlename />
        <lastname />
        <address>Department of hematology, the First Affiliated Hospital of Sun Yat-sen University, 58 Second Zhonshan Road, Guangzhou，Guangdong</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13570223456</telephone>
        <email>hbh_st@126.com</email>
        <affiliation>The First Affiliated Hospital of Sun Yat-sen University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Juan Li</firstname>
        <middlename />
        <lastname />
        <address>Department of hematology, the First Affiliated Hospital of Sun Yat-sen University, 58 Second Zhonshan Road, Guangzhou，Guangdong</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13719209240</telephone>
        <email>13719209240@163.com</email>
        <affiliation>The First Affiliated Hospital of Sun Yat-sen University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1) Between 18 and 60 years old;
2) Patients who meet the 2014 IMWG multiple myeloma diagnostic criteria;
3) Patients with 4 or more prognostic scores according to the first part of the study;
4) Symptomatic, measurablenewly diagnosed MM patients;
5) ECOG behavior status between 0-3 level; expected survival time&gt; 6 months;
6) Did not receive any anti-tumor therapy before (except glucocorticoid alone);
7) No other malignancy history;
8) No other serious illnesses in conflict with this program;
9) Patients understand and are willing to participate in this clinical trial and provide signed informed consent;
10) All patients must agree to take effective contraceptives during the study and in the termination of treatment within 6 months, women of childbearing age must be negative in the pregnancy test before treatment.</inclusion_criteria>
      <agemin>18</agemin>
      <agemax>60</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1) Have participated in other clinical studies in the last 3 months;
2) Secondary myeloma after chemotherapy or radiotherapy of other malignant tumors;
3) Received treatment for multiple myeloma before enrollment (except glucocorticoid alone);
4) Any other malignancy history before or at the time of diagnosis;
5) Decompensated heart failure, dilated cardiomyopathy, ECG showed significant reduction in ST segment of coronary heart disease and myocardial infarction occurred in the last 6 months;
6) Patients with uncontrolled severe infection or organic disease;
7) Liver dysfunction (transaminase exceeds the normal value limit of 4 times and / or blood bilirubin &gt; 2.0mg / dl);
8) Have brain disorders or severe mental illness;
9) Lactating or pregnant women.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Progression Free Survival;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>efficacy rate;overall survival;minimal residual disease;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Clinical Medicine Research 5010 Project of Sun Yat - sen University </source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-07-20</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>